Melatonin and Women's Hormones: What to Know Before Taking It Nightly

Melatonin is not a sleeping pill

This is the most important thing to understand about melatonin — and the most commonly misunderstood. Melatonin does not cause sedation. It doesn't knock you out. It's a circadian signal.

Produced by the pineal gland in response to darkness, melatonin tells your body "it's nighttime now" — which initiates the cascade of physiological changes that prepare you for sleep: core temperature drops, cortisol decreases, growth hormone begins to rise. Taking melatonin tells your brain to start that sequence earlier. It shifts your sleep timing. It does not deepen sleep or extend it.

This means melatonin is genuinely useful for: jet lag, shift work, delayed sleep phase (difficulty falling asleep until very late), and the natural melatonin decline that comes with age. It is not particularly useful for: staying asleep, getting deeper sleep, or treating anxiety-driven insomnia. The mechanism doesn't support those applications, and the research largely confirms this.

The dose confusion that affects most women taking it

Walk into any pharmacy and the melatonin you'll find is 3mg, 5mg, or 10mg. The evidence-supported dose for sleep onset is 0.5–1mg.

A review published in JAMA Internal Medicine found that doses above 1mg produced no additional sleep benefit and that most OTC melatonin doses are pharmacological rather than physiological — meaning they flood the system rather than providing a natural-signal equivalent. The sleep research literature consistently uses 0.5–1mg for phase-shifting effects, not the higher doses that dominate OTC products.

Why does this matter? Taking 10x the effective dose doesn't make melatonin work better. In some women, it leaves them groggy the next morning (melatonin has a 4–8 hour half-life), disrupts the natural rise and fall of the hormone, and may contribute to the sense that "it's stopped working" after a few weeks.

What melatonin does in the female reproductive system

Melatonin receptors are present in the ovaries, and melatonin directly influences follicular development, ovulation timing, and luteinization. Follicular fluid contains concentrations of melatonin that are 3-fold higher than in the bloodstream — suggesting the ovary actively concentrates it.

The proposed mechanism: melatonin acts as an antioxidant inside the follicle, neutralizing reactive oxygen species produced during folliculogenesis and ovulation. Oocytes are particularly vulnerable to oxidative damage, and older eggs (in women over 35 with diminished ovarian reserve) show the highest levels of oxidative stress. This is why reproductive medicine researchers have been particularly interested in melatonin as a potential adjunct in women undergoing IVF, specifically those with poor egg quality.

There's also a positive correlation between melatonin and progesterone levels in follicular fluid — suggesting a relationship between adequate melatonin signaling and the luteal phase. For women with short luteal phases or luteal insufficiency, this connection is worth knowing about.

Melatonin in perimenopause: what changes

Melatonin production naturally declines with age, starting in the mid-40s in most women and accelerating with menopause. The peak nocturnal melatonin secretion in a 60-year-old woman is typically a fraction of what it was in her 20s.

This decline is one reason why older adults tend to sleep lighter, wake earlier, and feel less alert in the evening. It also contributes to the sleep disruption of perimenopause — alongside the more talked-about factors of estrogen fluctuation and night sweats.

For perimenopausal women with circadian-type sleep disruption (difficulty falling asleep, early morning waking), low-dose melatonin used at the right time — 30–60 minutes before desired bedtime — has more mechanistic plausibility than it does for younger women with anxiety-driven insomnia.

When to be cautious: pregnancy, lactation, and adolescents

Melatonin crosses the placenta, and exogenous melatonin during pregnancy can influence fetal circadian programming. The current evidence base does not include adequate clinical trials in pregnant women to establish safety. Multiple reproductive medicine sources specifically recommend against melatonin during pregnancy except under direct medical supervision for specific conditions, such as preeclampsia research protocols.

In breastfeeding, melatonin passes into breast milk. Human data on infant effects is insufficient to make a safety determination.

Long-term daily use in otherwise healthy women: this is genuinely under-researched. Short-term safety is well-established even at doses far higher than the physiological range. Whether chronic daily supplementation suppresses endogenous melatonin production over time is not definitively answered in the current literature. This isn't a reason to avoid it — it's a reason to not assume it's consequence-free indefinitely.